Key result
Modified mRNA technology shows potential for treating cardiovascular diseases via cardiac regeneration, apoptosis inhibition, and immune modulation, though clinical challenges remain.
Why the study?
Despite advancements in pharmacotherapy, interventional techniques, and surgical approaches for cardiovascular diseases, many challenges persist, highlighting the need to explore modified mRNA technology to restore or enhance heart function.
Modified mRNA technology demonstrates pre-clinical potential for cardiovascular regeneration, apoptosis inhibition, and vaccine development, though clinical translation challenges remain.
mRNA therapies for CVD remain experimental; leaves open clinical translation until rigorous trials confirm benefits.
Cardiovascular diseases are one of the leading causes of death worldwide, significantly impacting the quality of life for millions of people individuals. Despite advancements in treatment modalities, including pharmacotherapy, interventional techniques, and surgical approaches, many challenges persist. In recent years, the development of messenger ribonucleic acid (mRNA) technology has provided new possibilities for treating heart disease. mRNA therapy utilizes the body’s translation mechanisms to generate specific proteins that may restore or enhance heart function, demonstrating tremendous clinical potential. This review summarizes strategies to optimize the efficiency of modified mRNA (modRNA)-targeted cardiac delivery. We also review pre-clinical development of modRNA technology to modulate cardiovascular regeneration, cardiomyocyte proliferation, apoptosis inhibition, and fibrosis inhibition. Furthermore, we examine the design of modRNA vaccines to stimulate the immune system for the removal of abnormal cells or repair of damaged tissues in heart disease. Finally, we address the current challenges and limitations of mRNA-based therapies for cardiovascular diseases, highlighting opportunities for future advancements.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2025) conducted a review in Cardiovascular diseases. Modified mRNA (modRNA) technology was evaluated. Modified mRNA technology shows potential for treating cardiovascular diseases via cardiac regeneration, apoptosis inhibition, and immune modulation, though clinical challenges remain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: